Search results
Results from the WOW.Com Content Network
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement.
The now-dead funding deal would have required PBMs to provide more information on the rebates they negotiate and retain, as well as what they pay for drugs and how much they compensate pharmacies.
Drug companies can price new medicines, particularly orphan drugs, i.e. drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients, at a cost that no individual person could pay, [73] [74] [75] because an insurance company or the government are payors. [76]
Medication costs can be the selling price from the manufacturer, that price together with shipping, the wholesale price, the retail price, and the dispensed price. [3]The dispensed price or prescription cost is defined as a cost which the patient has to pay to get medicines or treatments which are written as directions on prescription by a prescribers. [4]
And the annual list price of Merck’s cancer drug Keytruda is $191,000 in the US, while in the UK, it’s $115,000; in Canada, it’s $112,000; in France, it’s $91,000; in Germany, it’s ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Starting in fiscal year 2024, 50 drugs with the same criteria as before would need to have their price negotiated. Any newly approved, single-source, brand name drugs that exceeds a price threshold that the HHS has set that was determined to likely to meet the spending criteria. The negotiated drug prices would have to meet the following criteria:
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.